Abstract
Introduction
Osteoporosis, characterized by low bone mineral density (BMD) and increased fracture risk, is a serious health concern in the growing older population. Osteoporosis-related fractures are associated with increased morbidity and mortality and high economic costs, which underscores the need to clarify underlying mechanisms 1 . Although the pathogenesis of osteoporosis is presumed to be multifactorial, it has been suggested that the growth hormone (GH) -insulin-like growth factor 1 (IGF-1) axis plays a role [2] [3] [4] .
GH and IGF-1 are major regulators of bone metabolism. Although GH may have direct effects on bone, most of its effects are thought to be mediated through IGF-1, which is present in both the systemic circulation and peripheral tissues 2, 4 . The GH-IGF-1 axis is a key factor in longitudinal bone growth, acquisition of bone mass, and maintenance of adult bone mass 2, 4, 5 . In adults, severe growth hormone deficiency (GHD), mostly due to pituitary disorders, is associated with adverse changes in body composition, low BMD and probably increased fracture risk 2, 4, [6] [7] [8] . Growth hormone replacement therapy increases BMD in these patients and possibly reduces fracture risk 2, [8] [9] [10] [11] .
During normal aging, there is a natural decline in GH and IGF-1 concentrations, a phenomenon also known as the 'somatopause'. Because some features of aging, such as decreased muscle and bone mass, are similar to features of adult GHD, it has been proposed that the 'somatopause' contributes to the development of age-related diseases 12 . This has also been hypothesized for osteoporosis because the 'somatopause' parallels the decrease in bone mass with aging. However, this possible relationship still has to be elucidated.
Previous studies investigating the relationship between IGF-1 concentration and BMD in healthy adults have shown varying results. In some studies IGF-1 was positively associated with BMD, whereas in others no associations were found 3, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . Furthermore, whereas in two large cohort studies associations were only observed in women, in another study associations were only observed in men [14] [15] [16] . In addition, only a few of these studies have examined this association prospectively, whereas others included both younger and older adults.
The relationship between IGF-1 concentration and osteoporotic fractures has been examined in several studies [22] [23] [24] [25] [26] [27] [28] [29] [30] . To our knowledge, only two prospective studies have investigated the link between IGF-1 and risk of fractures in older persons 24, 26 . Both studies found an increased fracture risk in persons with lower IGF-1 concentrations.
However, one study included only men, whereas the other included only women.
The aim of the present study was to investigate cross-sectional relationships between serum IGF-1 concentration and bone parameters, including quantitative ultrasound (QUS) and BMD, as well as longitudinal relationships between baseline serum IGF-1 concentration and three-year change in BMD and ten-year osteoporotic fracture risk in community-dwelling older men and women.
Subjects and methods

Study population
Data for this study were collected within the framework of the Longitudinal Aging Study Amsterdam (LASA). LASA is an ongoing multidisciplinary cohort study in community-dwelling elderly subjects, representative of the older Dutch population.
Data collection and sampling procedures have previously been described elsewhere 31 .
Briefly, a random sample of men and women aged 55 -85 years, stratified by age, sex, urbanization, and expected five-year mortality rate, was drawn from the population registers of 11 municipalities in three regions in the Netherlands. At the LASA baseline (1992/1993), 3107 subjects (99% Caucasian) were enrolled. Examinations were performed at baseline and every three years thereafter. Informed consent was obtained from all participants. The study was approved by the Medical Ethics
Committee of the VU University Medical Center (VUmc) .
For the present study, respondents participating in the second LASA data collection cycle (1995/1996) aged 65 year or older as of January 1 st 1996 (n = 1509) were selected because blood samples for IGF-1 measurements were collected in these respondents (n = 1319). Participants using recombinant GH or systemic corticosteroids (n = 20) or with decreased renal function (creatinine > 200 µmol/l) or clinical hypothyroidism (n = 16) were excluded, resulting in a total study population of 1283 subjects.
Compared to those included in the study, those not included or without an IGF-1 measurement (n = 226) had a similar gender (p = 0.25) and smoking status (p = 0.08), but they were older, used less alcohol, and reported less physical activity (p ≤ 0.05).
QUS measurements were available for 1261 respondents. BMD was measured in a subsample of respondents from Amsterdam, resulting in baseline measurements of the total hip and femoral neck in 504, total lumbar spine in 517, and total body in 503 respondents. Follow-up BMD measurements at these sites were performed in 324, 336 and 328 respondents, respectively. A ten-year fracture follow-up was available for 1274 respondents.
Measurements
Serum IGF-1
In 1995/1996, blood samples were drawn in the morning and centrifuged within 60 minutes after withdrawal. Participants were allowed to take tea and toast beforehand, but no dairy products. Samples were kept frozen until determination in 1999. IGF-1 concentrations were determined by an immunoradiometric assay after extraction (Diagnostic Systems Laboratories) at the Endocrine Laboratory of the VUmc.
The detection limit was 1 nmol/l, the intra-assay coefficient of variation (CV) < 4%, and the inter-assay CV was < 14%. For the method used, the reference range values (5 -95%) of serum IGF-1 in persons aged 60 -70 years were 11 -19 nmol/l for both men and women. Although some subjects had an IGF-1 concentration above the reference rage, no signs of incorrect sample treatment or storage problems were detected. Because the reference range for persons aged > 70 years was not defined, it was assumed that the higher concentrations were at the upper part of the reference range. IGF-1 concentrations were normally distributed over the study population.
QUS measurements
In 1995/1996, QUS measurements of the heel, including broadband ultrasound attenuation (BUA) and speed of sound (SOS), were performed using the CUBA Clinical 
BMD measurements
In 1995/1996 and in 1998/1999, dual X-ray absorptiometry was performed at the VUmc using a Hologic QDR 2000 scanner (Hologic Inc). The right hip was scanned for measurements of the hip region. In 12 subjects, including respondents with a rightsided hip prosthesis, the left hip was scanned. BMD of the total hip, femoral neck, total lumbar spine and total body was measured in grams per square centimeter.
Fractures
Between 1995/1996 and 1998/1999, data on fractures were collected with a fracture calendar. Participants were instructed to complete a set of questions regarding fractures every three months and return these to the study center. 
Potential confounders
Sociodemographic, lifestyle and health status variables were measured at baseline.
Data on age and sex were derived from the population registries. Smoking behavior and alcohol consumption were assessed by self-report. Physical activity in the previous two weeks was measured with the LASA Physical Activity Questionnaire 33 .
Body mass index (BMI) was calculated as body weight divided by height squared (kg/m 2 ). Serum albumin concentrations were analyzed in three different Dutch laboratories. For comparison, the results were converted with a validated formula 34 .
Serum creatinine concentration was measured with a Hitachi 747 analyzer. The number of chronic diseases was assessed by self-report, which included questions regarding the following seven major diseases: pulmonary disease, cardiac disease, peripheral arterial diseases, diabetes mellitus, stroke, osteoarthritis/rheumatoid arthritis, and malignancies.
Other variables
Other variables of interest were also measured at baseline. Education was assessed by asking respondents for their highest educational level. Thyroid hormones were determined in frozen samples at the Endocrine Laboratory of the VUmc in 2001.
Plasma fructosamine, total cholesterol, and high-density lipoprotein cholesterol were measured by (enzymatic) colorimetric tests. Fructosamine was measured instead of glucose because not all subjects were completely fasting (tea and toast allowed) when blood samples were taken, and fructosamine is little affected by eating 35 . Testosterone, which was only determined in males, was measured by a radioimmunoassay. Serum total cortisol, collected in the morning, was determined using a competitive immunoassay.
The use of estrogens, bisphosphonates, systemic corticosteroids and recombinant 
Statistical analysis
Linear regression analyses were used to study the associations between baseline IGF-1 concentration and measurements of QUS and BMD, respectively. Assumptions
of linear regression analyses were tested by histograms and normal probability plots.
All independent continuous variables were individually checked for linearity with the outcome variables and, in case of nonlinearity, divided into categories. IGF-1 was divided into quintiles (Qs), with the fifth quintile (Q5) representing the highest
IGF-1 concentrations. To test for relevant confounding, all potential confounders
were added separately to the age-and gender-adjusted models. Variables that gave a change in the regression coefficient of > 10% were included in the models. In the longitudinal analyses between IGF-1 concentration and three-year change in BMD measurements, baseline BMD was also examined for relevant confounding.
To test for effect modification, interaction terms between IGF-1 and the potential effect modifiers (gender and total testosterone concentration) were added to all fully adjusted models. In case of a p-value < 0.10, analyses were presented in stratified groups. For comparability reasons, all analyses were stratified for gender because effect modification by gender was found in some analyses but not in others.
Cox proportional hazard analysis was used to examine the longitudinal association between baseline IGF-1 concentration and osteoporotic fracture risk. Assumptions of proportional hazards were tested by log-minus-log plots and interaction terms. Time was measured from baseline until the date of first fracture, death, or last follow-up.
Relevant confounding and effect modification were investigated in the same manner as in the linear regression analyses.
Sensitivity analyses were performed in all fully adjusted models by excluding respondents using estrogens or bisphosphonate. Furthermore, to assess the potential influence of mortality during follow-up, mortality was added as an additional confounder to the fully adjusted models examining three-year change in BMD and fracture risk. An additional sensitivity analysis was also performed for fracture risk by excluding fractures that could not be verified. All statistical analyses were performed using the statistical software package IBM SPSS Statistics version 20. Two-sided p-values of ≤ 0.05 were considered significant.
Results
Characteristics
Baseline characteristics are shown in with and without a baseline BMD measurement (n = 517 and n = 766 respectively).
Effect modification
In all regression analyses, effect modification by gender or testosterone was investigated. A significant interaction with gender was observed in the analyses with BUA (p = 0.003) and fracture risk (p = 0.098), but not in those with SOS (p = 0.14) or the various BMD measurements (lowest p-value 0.27). For comparability reasons, all analyses were stratified for gender. Testosterone was not found to be a significant effect modifier.
Quantitative ultrasound
Women in Q1 of IGF-1 had significantly lower BUA than women in Q5 of IGF-1, also after adjustment for relevant confounders (age, BMI, albumin, alcohol, physical activity, creatinine, and smoking). In men, no significant associations between IGF-1 and BUA were observed (table 3) . The same analyses performed with SOS did not show significant associations in men or women after adjustment for relevant confounders (data not shown). Exclusion of respondents using estrogens or bisphosphonates (n = 25) from the fully adjusted models did not materially change the results.
Bone mineral density
In the cross-sectional analyses with total hip BMD, participants in Q1 of IGF-1 had a significantly lower BMD of the total hip than participants in Q5 of IGF-1 in both the associations between IGF-1 and BMD of the femoral neck, total lumbar spine, or total body were observed after adjustment for relevant confounders. Excluding respondents using estrogens or bisphosphonates (n = 10) from the fully adjusted models did not substantially influence any of the results.
As shown in table 4, women, but not men, in Q1 of IGF-1 had a greater decrease in total hip BMD over three years than women in Q5 of IGF-1, also after adjustment for relevant confounders (age, baseline total hip BMD, smoking, alcohol, physical activity, BMI, albumin, creatinine, and number of chronic diseases). All other analyses investigating three-year change in BMD of the femoral neck, total lumbar spine, or total body did not reveal significant associations. Exclusion of respondents using estrogens or bisphosphonates (n = 6) from all fully adjusted models resulted in similar associations. However, the association between IGF-1 and change in total hip BMD in women did not remain statistically significant (B = -0.01, 95% CI, -0.03 to 0.01). Addition For comparability, analyses were stratified for gender (lowest p-value interaction terms for gender 0.41). Analyses were not stratified for testosterone (lowest p-value interaction terms for testosterone ≥ 0.10). Fully adjusted model: adjusted for age, baseline total hip BMD, smoking status, alcohol consumption, physical activity, BMI, albumin, creatinine, and number of chronic diseases. Separate adjustment for age alone did not substantially influence the results (data not shown).
of mortality (n = 4 deaths during three years of follow-up) to the fully adjusted models did not materially change the results.
Fractures
During the ten-year follow-up, 148 of 1274 (11.6%) respondents had an osteoporotic fracture, of which 43 (29.1%) were hip fractures, 35 (23.6%) were wrist fractures, 18 (12.2%) were rib fractures, 13 (8.8%) were vertebral fractures, 12 (8.1%) were humerus fractures, and 27 (18.2%) were other fractures. Ninety-eight (15.%) women had a fracture during follow-up, compared to 50 (8.0%) men (p < 0.001). The number of fractures in Q1 to Q4 of IGF-1 concentration were similar to each other but higher than in Q5 (table 2) . Also, when compared to women in Q5, the hazard ratio's (HRs) for fractures for women in Q1 to Q4 were similar to each other in Cox proportional hazard 
Discussion
In this large cross-sectional and longitudinal study of community-dwelling older persons, the associations of serum IGF-1 concentration with QUS measurements, BMD measurements, and ten-year fracture risk were investigated. Women, but not men, in the lowest quintile of IGF-1 had lower BUA and a greater three-year decline in total hip BMD than women in the highest quintile of IGF-1. Moreover, women in the lowest four Previous studies exploring the relationships between serum IGF-1 and bone health in adults have shown heterogeneous results 3, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . Although positive relationships of IGF-1 with QUS or BMD were observed in some studies, no relationships were found in others 3, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [26] [27] [28] [29] [30] . Likewise, a lower IGF-1 concentration was associated with fractures in some studies, whereas this was not observed in others [22] [23] [24] [25] [26] [27] [28] [29] [30] . Inconsistencies in these findings may be due to differences in sample size, study population, confounding variables, or follow-up duration. Most of these studies had a cross-sectional design.
In the present study, a consistent gender difference was observed over time.
Overall, outcomes were worse for women with a lower IGF-1 concentration compared to women with a higher IGF-1 concentration, whereas in men no associations were
found. This marked gender difference is in accordance with findings in other populationbased studies including both men and women 14, 15, 21 . In the Rancho Bernardo study, a cross-sectional positive association between serum IGF-1 concentration and BMD was only observed in women 15 . Similarly, in a sample of 425 women and 275 men from the Framingham Heart Study, higher IGF-1 was associated with greater BMD in women 14 . In contrast, other investigators observed associations in men only 16, 26 . Reasons for the observed gender differences are unclear. Possibly, differences in hormonal status play a role. Older men generally have higher testosterone concentrations than older women, which may contribute to the preservation of bone health in men 18, 36, 37 .
An indirect effect of testosterone may also play a role because there is some evidence that testosterone may enhance the activity of the GH-IGF-1 axis 18, 36 . This is supported by the observed higher IGF-1 concentrations in men than in women in our cohort and in other cohorts 14, 15, 36 . On the other hand, testosterone was not found to be a significant effect modifier in the present study, although it was only measured in men. Furthermore, it has also been suggested that the GH-IGF-1 axis itself may alter sex hormone concentrations 18, 36, 38 . Moreover, estradiol may also be involved because testosterone may be aromatized to estradiol, which may result in relatively higher estradiol concentrations in elderly men 36, 37 . Although exclusion of subjects using estrogens did not substantially change the results in the present study, lower estrogen concentrations have been associated with osteoporosis, and it has been suggested that estrogen may influence the GH-IGF-1 axis 2,37 . Furthermore, differences in additional covariates may also be involved. However, because we adjusted for numerous lifestyle and health status variables in the present study, this seems less likely.
The finding of an increased ten-year fracture risk in women with lower IGF-1 concentrations is in line with findings in two other studies with shorter follow-up durations 24, 26 . Potential mechanisms underlying these findings are complex and largely unclear. A possible mechanism is the potentially stimulating effect of IGF-1 on bone formation 2, 4 . Lower IGF-1 may lead to decreased bone formation and lower BMD, which may result in increased fracture risk. Whether locally synthesized IGF-1 or systemic IGF-1 contributes more to these effects is a complex issue which still remains to be solved 2, 4 . An indirect effect of IGF-1 on bone health may also be possible because a potentially complex interaction between the GH-IGF-1 axis, the gonadal axis, and aging may also be involved 18, 36 . In addition, it has been postulated that lower IGF-1 may affect other factors, such as physical activity, body composition, or neuromuscular function, which may influence fracture risk 26, 39, 40 .
Although severe adult GHD is associated with adverse effects on body composition, these associations are less clear in relatively healthy older persons 6, 40, 41 . In the present study, BMI was not of major influence in the observed associations. In another prospective cohort study, neuromuscular function was not an important factor in the association between IGF-1 and fracture risk 26 . More research is needed to clarify these potential relationships.
Lower IGF-1 may also reflect a poor general health status or malnutrition in older individuals. Low protein intake may reduce not only IGF-1 concentration, but also neuromuscular function and bone mass, which could influence fracture risk 42, 43 .
Whether IGF-1 directly mediates these effects or is a marker of these conditions remains to be fully elucidated. In a randomized placebo-controlled trial among older patients with a recent osteoporotic hip fracture, oral protein supplementation was associated with an increase in IGF-1 concentration, attenuation of bone loss and a reduction in hospital stay 42 . In our study, adjustments for albumin, as an indicator for nutritional status, and other relevant founders, such as physical activity and number of chronic diseases, did not substantially alter the associations.
The strengths of the present study are the large number of community-dwelling older men and women included, the mixed cross-sectional and prospective design, the long follow-up duration, the comprehensive measurements of bone health, and the ability to adjust for various relevant confounders. Nevertheless, our study has several limitations. Only total serum IGF-1 concentration was measured, whereas IGFbinding protein concentrations, which may modulate the bioactivity and availability of IGF-1, were not measured. However, in another study relationships between free and total IGF-1and BMD were almost identical 16 . Another limitation is that local bone IGF-1 could not be measured with the available techniques. Nevertheless, it has been hypothesized that systemic IGF-1concentrations parallel bone IGF-1 concentrations 2,4 . Furthermore, although our analyses were adjusted for a variety of confounders, we cannot exclude the possibility that the observed associations may partly be explained by other nonmeasured variables. In addition, because our study population consisted primarily of relatively healthy, older Caucasian individuals, generalization of the findings to other populations should be performed with caution.
In conclusion, in this large prospective population-based study in older persons, low-normal IGF-1 concentration was cross-sectionally associated with lower BUA and prospectively with a greater three-year decrease in total hip BMD in women, but not in men. Moreover, women with lower IGF-1 concentrations had an increased risk of
